OncoMatch/Clinical Trials/NCT06343311
T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)
Is NCT06343311 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies EB103 for b-cell non-hodgkin's lymphoma (nhl).
Treatment: EB103 — This is an open-label, dose escalation, multi-center, Phase I/II clinical trial to assess the safety of an autologous T-cell therapy (EB103) and to determine the Recommended Phase II Dose (RP2D) in adult subjects (≥ 18 years of age) who have relapsed/refractory (R/R) B-cell NHL. The study will include a dose escalation phase followed by an expansion phase.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Non-Hodgkin Lymphoma
Diffuse Large B-Cell Lymphoma
Primary Central Nervous System Lymphoma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: anti-CD20 monoclonal antibody
All subjects must have received an appropriate chemoimmunotherapy regimen which at a minimum includes an: Anti-CD20 monoclonal antibody
Must have received: anthracycline-containing chemotherapy regimen
All subjects must have received an appropriate chemoimmunotherapy regimen which at a minimum includes an: ... anthracycline-containing chemotherapy regimen
Cannot have received: CD19-targeted cellular therapy
Prior CD19-targeted cellular therapy
Lab requirements
Blood counts
Kidney function
Liver function
Adequate organ function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of California, Davis · Sacramento, California
- Baylor Scott & White Research Institute, Texas Oncology · Dallas, Texas
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06343311 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior CD19-targeted cellular therapy disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify